




Fluoroestradiol F18

Revised: May 15, 2023.

CASRN: 94153-53-4



Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of fluoroestradiol F18 (18F-FES) as a diagnostic agent. No information is available on the clinical use of fluoroestradiol F18 during breastfeeding. The manufacturer recommends that mothers avoid breastfeeding for 4 hours after administration of fluoroestradiol F18. Nursing mothers should not work with radioactive substances used in PET scans in their workplace.[1]

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Drug Levels

F18 is a positron emitter with a principal decay energy of 0.6335 MeV, annihilation photons of 0.511 MeV, and a physical half-life of 1.8 hours and 0.07% of an administered dose appears in breastmilk.[2] The maximum effective half-life is 0.89 hours.[3]

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Almén A, Mattsson S. Radiological protection of foetuses and breast-fed children of occupationally exposed women in nuclear medicine - Challenges for hospitals. *Phys Med.* 2017;43:172–7. PubMed PMID: 28882410.
2. Leide-Svegborn S, Ahlgren L, Johansson L, et al. Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption. *Eur J Nucl Med Mol Imaging.* 2016;43:808–21. PubMed PMID: 26732471.
3. ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. Available at: <https://www.gov.uk/government/publications/arsac-notes-for-guidance>

Substance Identification

Substance Name

Fluoroestradiol F18

CAS Registry Number

94153-53-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Radiopharmaceuticals

Diagnostic Agents